FGF21 and cardiomyopathy: Conversely, using genetic or pharmacological modulation, FGF21 displays cardioprotective properties under dysregulated glucose and lipid metabolism (55–57) FGF21 also promotes lipophagy in mouse cardiomyocytes in obesity-related cardiomyopathy by preventing lipid accumulation (58).